A new study reported that metformin can restore mitochondrial quality control in Down syndrome fibroblasts. Published in Cellular and Molecular Life Sciences, the work links the drug to improvements in cellular pathways that help manage mitochondrial health—an issue central to Down syndrome biology. The research frames mitochondrial dysfunction as a continuing target for therapeutic strategies that go beyond symptomatic care. By focusing on quality control mechanisms, the study suggests metformin may influence cellular “maintenance” systems rather than only metabolic readouts. While the provided summary focuses on cell-model findings, it supports further translation efforts to validate whether the mitochondrial quality control improvements observed in fibroblasts map to functional outcomes in more relevant systems. The findings add to metformin’s expanding portfolio of research uses in neuro-metabolic contexts, where mitochondrial impairment is frequently implicated.